The effect of guideline revisions on vascular complications of type 2 diabetes

Background: The aim of this study was to investigate the impact of implementation and revision of the ‘Diabetes Mellitus type II’ guideline by the Dutch College of General Practitioners (DCGP) on the prevalence and incidence of macrovascular and microvascular complications. Methods: The DiaGene stud...

Full description

Bibliographic Details
Main Authors: Ralph Heijmans, Sunny S. Singh, Aloysius G. Lieverse, Eric J.G. Sijbrands, Mandy van Hoek
Format: Article
Language:English
Published: SAGE Publishing 2019-09-01
Series:Therapeutic Advances in Endocrinology and Metabolism
Online Access:https://doi.org/10.1177/2042018819875408
id doaj-dbc49964f4fb4ca4a236faa9df7b828a
record_format Article
spelling doaj-dbc49964f4fb4ca4a236faa9df7b828a2020-11-25T03:52:56ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01962019-09-011010.1177/2042018819875408The effect of guideline revisions on vascular complications of type 2 diabetesRalph HeijmansSunny S. SinghAloysius G. LieverseEric J.G. SijbrandsMandy van HoekBackground: The aim of this study was to investigate the impact of implementation and revision of the ‘Diabetes Mellitus type II’ guideline by the Dutch College of General Practitioners (DCGP) on the prevalence and incidence of macrovascular and microvascular complications. Methods: The DiaGene study is a case-control study ( n  = 1886 patients of type 2 diabetes) with extensive, retrospectively collected complication data, as well as prospective follow up of complications. The study incorporates all lines of diabetes care. Cases were divided into categories according to the date of onset of diabetes and publication dates of the DCGP. Logistic regression models were used to investigate the associations between guideline version and complications. To investigate a possible trend between guideline version and complications, the ‘guideline category’ was also used as a continuous variable. All models were adjusted for clinical covariables. Results: The 1999 and 2006 guidelines versions were associated with significantly lower risk of retinopathy than the group that started without a guideline [OR 0.32 (95% CI 0.14–0.72, p  = 0.006) and 0.31 (95% CI 0.11–0.91, p  = 0.034), respectively]. A significant trend in reduction of peripheral artery disease (PAD) over the guideline versions was found, adjusted for age, sex and diabetes duration (odds ratio (OR) 0.70, 95% CI 0.51-0.97, p trend = 0.029) and for retinopathy in all models (OR = 0.52, 95% CI 0.37-0.73, p trend < 0.001). Conclusions: The introduction of the first diabetes guideline and subsequent revisions have reduced the risk of macrovascular and microvascular complications of type 2 diabetes, most strongly in diabetic retinopathy. This indicates that real-time diabetes care has improved over time.https://doi.org/10.1177/2042018819875408
collection DOAJ
language English
format Article
sources DOAJ
author Ralph Heijmans
Sunny S. Singh
Aloysius G. Lieverse
Eric J.G. Sijbrands
Mandy van Hoek
spellingShingle Ralph Heijmans
Sunny S. Singh
Aloysius G. Lieverse
Eric J.G. Sijbrands
Mandy van Hoek
The effect of guideline revisions on vascular complications of type 2 diabetes
Therapeutic Advances in Endocrinology and Metabolism
author_facet Ralph Heijmans
Sunny S. Singh
Aloysius G. Lieverse
Eric J.G. Sijbrands
Mandy van Hoek
author_sort Ralph Heijmans
title The effect of guideline revisions on vascular complications of type 2 diabetes
title_short The effect of guideline revisions on vascular complications of type 2 diabetes
title_full The effect of guideline revisions on vascular complications of type 2 diabetes
title_fullStr The effect of guideline revisions on vascular complications of type 2 diabetes
title_full_unstemmed The effect of guideline revisions on vascular complications of type 2 diabetes
title_sort effect of guideline revisions on vascular complications of type 2 diabetes
publisher SAGE Publishing
series Therapeutic Advances in Endocrinology and Metabolism
issn 2042-0196
publishDate 2019-09-01
description Background: The aim of this study was to investigate the impact of implementation and revision of the ‘Diabetes Mellitus type II’ guideline by the Dutch College of General Practitioners (DCGP) on the prevalence and incidence of macrovascular and microvascular complications. Methods: The DiaGene study is a case-control study ( n  = 1886 patients of type 2 diabetes) with extensive, retrospectively collected complication data, as well as prospective follow up of complications. The study incorporates all lines of diabetes care. Cases were divided into categories according to the date of onset of diabetes and publication dates of the DCGP. Logistic regression models were used to investigate the associations between guideline version and complications. To investigate a possible trend between guideline version and complications, the ‘guideline category’ was also used as a continuous variable. All models were adjusted for clinical covariables. Results: The 1999 and 2006 guidelines versions were associated with significantly lower risk of retinopathy than the group that started without a guideline [OR 0.32 (95% CI 0.14–0.72, p  = 0.006) and 0.31 (95% CI 0.11–0.91, p  = 0.034), respectively]. A significant trend in reduction of peripheral artery disease (PAD) over the guideline versions was found, adjusted for age, sex and diabetes duration (odds ratio (OR) 0.70, 95% CI 0.51-0.97, p trend = 0.029) and for retinopathy in all models (OR = 0.52, 95% CI 0.37-0.73, p trend < 0.001). Conclusions: The introduction of the first diabetes guideline and subsequent revisions have reduced the risk of macrovascular and microvascular complications of type 2 diabetes, most strongly in diabetic retinopathy. This indicates that real-time diabetes care has improved over time.
url https://doi.org/10.1177/2042018819875408
work_keys_str_mv AT ralphheijmans theeffectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT sunnyssingh theeffectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT aloysiusglieverse theeffectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT ericjgsijbrands theeffectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT mandyvanhoek theeffectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT ralphheijmans effectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT sunnyssingh effectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT aloysiusglieverse effectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT ericjgsijbrands effectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
AT mandyvanhoek effectofguidelinerevisionsonvascularcomplicationsoftype2diabetes
_version_ 1724480116406353920